Apixaban for Treatment of Embolic Stroke of Undetermined Source

Inclusion criteria Must be ≥ 18 years at the time of signing the informed consent. * ESUS must be defined according to following criteria: * Stroke detected by CT or MRI that is not lacunar * Absence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the area of ischaemia * No major-risk cardioembolic source of embolism * No other specific cause of stroke identified * \* At least one of the following non-major but suggestive risk factors for cardiac embolism: * LA size \>45mm (parasternal axis) * spontaneous echo contrast in LAA * LAA flow velocity \<=0.2m/s * atrial high rate episodes * CHA2DS2-Vasc score \>=4 * persistent foramen ovale * Understand and voluntarily sign an informed consent document * Women of childbearing potential (WOCBP) must be using an adequate method of contraception. Exclusion Criteria: * History of hypersensitivity to the investigational medicinal product * Participation in other clinical trials or observation period of competing trials. * Arteria cerebri media stroke affecting \> 30% of c o r r e s p o n d i n g territory * Diagnosis of haemorrhage or other pathology, * Clear indication for anticoagulation * Inability to control following risk factors for Hemorrhagic Transformation of fresh cerebral Infarction (HTI) during index hospital stay: presence of HTI at the time of anticoagulation, blood pressure \>140 mmHg systolic, abnormal blood glucose Clear indication for dual ant…